Seeds Investor LLC Cuts Position in Pfizer Inc. (NYSE:PFE)

Seeds Investor LLC lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 32.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 11,263 shares of the biopharmaceutical company’s stock after selling 5,367 shares during the period. Seeds Investor LLC’s holdings in Pfizer were worth $299,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. Retirement Wealth Solutions LLC acquired a new stake in shares of Pfizer in the 4th quarter worth approximately $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer during the 4th quarter worth $26,000. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Pfizer in the 4th quarter worth about $28,000. Noble Wealth Management PBC acquired a new stake in Pfizer in the 4th quarter valued at about $31,000. Finally, Bernard Wealth Management Corp. purchased a new position in Pfizer during the 4th quarter valued at about $33,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

PFE has been the topic of a number of recent research reports. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. The Goldman Sachs Group reissued a “neutral” rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. UBS Group lowered their price target on shares of Pfizer from $28.00 to $24.00 and set a “neutral” rating for the company in a report on Tuesday, April 8th. Finally, Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and an average target price of $31.07.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.06% of the company’s stock.

Pfizer Stock Performance

Shares of NYSE:PFE opened at $21.89 on Monday. The firm has a market capitalization of $124.14 billion, a PE ratio of 15.52, a P/E/G ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The business has a 50-day moving average of $25.25 and a two-hundred day moving average of $26.38.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.10 earnings per share. As a group, research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.